GSK3β Inhibition Ameliorates Atherosclerotic Calcification

Area of Science:

• Cardiovascular Biology
• Vascular Biology
• Molecular Medicine

Background:

• Endothelial-mesenchymal transition (EndMT) contributes to atherosclerotic calcification.
• Glycogen synthase kinase-3β (GSK3β) plays a role in regulating cell lineage and vascular calcification.
• Previous studies indicated GSK3β inhibition affects β-catenin and SMAD1, impacting osteoblast-like cells and vascular calcification.

Purpose of the Study:

• To investigate the role of GSK3β inhibition in reducing atherosclerotic calcification.
• To determine if GSK3β inhibition impacts β-catenin and SMAD1 pathways in atherosclerotic models.
• To explore the therapeutic potential of GSK3β inhibition for vascular calcification.

Main Methods:

• Utilized mouse models of atherosclerosis (Apoe knockout mice).
• Administered GSK3β inhibitors and employed endothelial-specific GSK3β deletion.
• Analyzed molecular changes in aortic tissues, focusing on β-catenin and SMAD1 expression.

Main Results:

• GSK3β inhibition significantly reduced atherosclerotic calcification in Apoe knockout mice.
• Endothelial-specific deletion of GSK3β also decreased atherosclerotic calcification.
• GSK3β inhibition modulated β-catenin and SMAD1 levels in the aorta, similar to findings in Mgp-deficient mice.

Conclusions:

• GSK3β inhibition is a viable strategy to reduce atherosclerotic calcification.
• The mechanism involves the modulation of β-catenin and SMAD1 pathways, redirecting cells towards an endothelial lineage.
• This approach shows promise for treating vascular calcification in atherosclerosis.